BioSpace News Archive

Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the closing of its initial public offering of 9,511,075 of its ordinary shares

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it is commencing an underwritten public o

- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 fourth quarter and full year financial results on Tuesday, February 23, 2021 , after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST / 9:30 p.m. GMT

Inogen to Announce Fourth Quarter and Year End 2020 Financial Results on February 24 th , 2021

- Fourth Quarter 2020 QINLOCK® Net Revenue of $19.5 Million and Full Year 2020 QINLOCK Net Revenue of $39.5 Million - - Top-line Results in INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line GIST Expected in the Second Half of 2021 - - Pipeline Candidates, Vimseltinib (DCC-3014), Rebastinib and DCC-3116, Continue to Advance with Significant Clinical Milestones Expected in 2021 -

Amedisys, Inc., announced that it will report results for the fourth quarter and year ended December 31, 2020, after the market closes on February 24, 2021.

PRC, a leader in healthcare experience solutions, announced today it has received a contract with Vizient, the largest member-driven, performance improvement company in the country

The global oncology market will be substantially driven by the rise in various government and non-government initiatives to curb the occurrence of cancer diseases.

The advanced wound care market growth will be driven by robust technological advancement in the medical field, a substantial rise in geriatric population, and numerous government initiatives to enhance healthcare infrastructure.